Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

doi:10.1002/hep.24696

Editorial

. 2011 Nov;54(5):1503-5.

doi: 10.1002/hep.24696.

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Kathleen E Corey, Naga Chalasani

PMID: 21953015
PMCID: PMC3644213
DOI: 10.1002/hep.24696

Free PMC article

Editorial

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Kathleen E Corey et al. Hepatology. 2011 Nov.

Free PMC article

. 2011 Nov;54(5):1503-5.

doi: 10.1002/hep.24696.

Authors

Kathleen E Corey, Naga Chalasani

PMID: 21953015
PMCID: PMC3644213
DOI: 10.1002/hep.24696

No abstract available

PubMed Disclaimer

Comment on

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Torres DM, et al. Hepatology. 2011 Nov;54(5):1631-9. doi: 10.1002/hep.24558. Hepatology. 2011. PMID: 21748770 Clinical Trial.

Cited by

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome.
Zhang H, Gao X, Chen P, Wang H. Zhang H, et al. Front Pharmacol. 2022 May 2;13:851267. doi: 10.3389/fphar.2022.851267. eCollection 2022. Front Pharmacol. 2022. PMID: 35586044 Free PMC article.
Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Vos MB, et al. Hepatology. 2022 Aug;76(2):429-444. doi: 10.1002/hep.32403. Epub 2022 Feb 28. Hepatology. 2022. PMID: 35133671 Free PMC article. Clinical Trial.
Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine.
Mueller AM, Kleemann R, Gart E, van Duyvenvoorde W, Verschuren L, Caspers M, Menke A, Krömmelbein N, Salic K, Burmeister Y, Seilheimer B, Morrison MC. Mueller AM, et al. Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815271 Free PMC article.
Therapeutic pipeline in nonalcoholic steatohepatitis.
Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Vuppalanchi R, et al. Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):373-392. doi: 10.1038/s41575-020-00408-y. Epub 2021 Feb 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33568794 Review.
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis.
Noureddin M, Muthiah MD, Sanyal AJ. Noureddin M, et al. Endocrinol Diabetes Metab. 2019 Dec 10;3(4):e00105. doi: 10.1002/edm2.105. eCollection 2020 Oct. Endocrinol Diabetes Metab. 2019. PMID: 33102791 Free PMC article. Review.

References

1. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50:1087–1093. - PubMed
1. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–788. - PubMed
1. Musso G, Gambino R, Cssader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104. - PubMed
1. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia j, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic steatohepatitis Clinical Research Network. JAMA. 2011;305:1659–1668. - PMC - PubMed
1. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

K24 DK069290/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50:1087–1093. - PubMed

[2] Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009;50:1087–1093. - PubMed

[3] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–788. - PubMed

[4] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–788. - PubMed

[5] Musso G, Gambino R, Cssader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104. - PubMed

[6] Musso G, Gambino R, Cssader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104. - PubMed

[7] Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia j, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic steatohepatitis Clinical Research Network. JAMA. 2011;305:1659–1668. - PMC - PubMed

[8] Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia j, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic steatohepatitis Clinical Research Network. JAMA. 2011;305:1659–1668. - PMC - PubMed

[9] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. - PMC - PubMed

[10] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Authors

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources